Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Mick

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Journal of the National Cancer Institute|February 3, 1993
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precisionR Mick, M J Ratain
Clinical Pharmacology and Therapeutics|August 1, 1994
Bootstrap validation of pharmacodynamic models defined via stepwise linear regressionR Mick, M J Ratain
Cancer Chemotherapy and Pharmacology|January 1, 1993
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptionsR Mick, M J Ratain
Journal of the National Cancer Institute|November 6, 1991
Modeling interpatient pharmacodynamic variability of etoposideR Mick, M J Ratain
Zeitschrift Fur Geburtshilfe Und Perinatologie|December 1, 1978
[Influence of an active attitude towards induction of labour, on the occurrence of pathological amniotic fluid - a comparison of the birth years 1967 and 1976 (author's transl)]W Grünberger, R Mick, P Wagenbichler
Gynecologic and Obstetric Investigation|January 1, 1980
First-trimester serum prolactin levels in normal and complicated pregnanciesP Riss, R Mick, J Spona
Acta Haematologica|January 1, 1994
Hematuria in sickle cell anemia--not always benign: evidence for excess frequency of sickle cell anemia in African Americans with renal cell carcinomaB W Baron, R Mick, J M Baron
Cancer|August 15, 1993
Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disordersB W Baron, R Mick, J M Baron
Controlled Clinical Trials|July 29, 2000
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpointR Mick, J J Crowley, R J Carroll
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group BR O Dillman, R Mick, O R McIntyre
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Journal of the National Cancer Institute|February 3, 1993
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precisionR Mick, M J Ratain
Clinical Pharmacology and Therapeutics|August 1, 1994
Bootstrap validation of pharmacodynamic models defined via stepwise linear regressionR Mick, M J Ratain
Cancer Chemotherapy and Pharmacology|January 1, 1993
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptionsR Mick, M J Ratain
Journal of the National Cancer Institute|November 6, 1991
Modeling interpatient pharmacodynamic variability of etoposideR Mick, M J Ratain
Zeitschrift Fur Geburtshilfe Und Perinatologie|December 1, 1978
[Influence of an active attitude towards induction of labour, on the occurrence of pathological amniotic fluid - a comparison of the birth years 1967 and 1976 (author's transl)]W Grünberger, R Mick, P Wagenbichler
Gynecologic and Obstetric Investigation|January 1, 1980
First-trimester serum prolactin levels in normal and complicated pregnanciesP Riss, R Mick, J Spona
Acta Haematologica|January 1, 1994
Hematuria in sickle cell anemia--not always benign: evidence for excess frequency of sickle cell anemia in African Americans with renal cell carcinomaB W Baron, R Mick, J M Baron
Cancer|August 15, 1993
Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disordersB W Baron, R Mick, J M Baron
Controlled Clinical Trials|July 29, 2000
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpointR Mick, J J Crowley, R J Carroll
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group BR O Dillman, R Mick, O R McIntyre
Pageof 13